BACKGROUND Vaccine-elicited adaptive immunity is a prerequisite for control of SARS-CoV-2
infection. Multiple sclerosis (MS) disease-modifying therapies (DMTs) differentially target …

Background The immunogenicity of COVID-19 vaccine among patients receiving anti-CD20
monoclonal antibody (Ab) treatment has not been fully investigated. Detectable levels of …

Objective To determine the transfer of rituximab, an anti-CD20 monoclonal antibody widely
used for neurologic conditions, into mature breast milk. Methods Breast milk samples were …

Background Adequate response to the SARS-CoV-2 vaccine represents an important
treatment goal in caring for patients with multiple sclerosis (MS) during the ongoing COVID-19 …

Objective To evaluate radiologic and clinical inflammatory activity in women with MS during
pregnancy and postpartum. Methods We performed a retrospective analysis of prospectively …

Vaccine-elicited adaptive immunity is an essential prerequisite for effective prevention and
control of coronavirus 19 (COVID-19). Treatment of multiple sclerosis (MS) involves a diverse …

Introduction Self-administered in-home digital therapeutics could expand access to cognitive
rehabilitation for individuals with multiple sclerosis (MS), over half of whom experience …

Objective: To assess whether a videogame-like digital treatment is superior to a control in
improving processing speed in adults with multiple sclerosis (MS). Methods: Adults with MS …

Background Patients with multiple sclerosis (MS) face several challenges in accessing
clinical tools to help them monitor, understand, and make meaningful decisions about their …

Background and Objectives Patients with multiple sclerosis (MS) transition from oral
sphingosine-1-receptor (S1P) modulators to anti-CD20 therapies for several circumstances. Optimal …